
Sign up to save your podcasts
Or


Daily - Nov 2, 2-26 — Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
Chapters
00:00 Today's Lead Biotech Stories
00:27 FDA Grants Accelerated Approval to VOCERYQ
00:53 INOVIO Confirmatory Trial and Launch Timeline
01:10 Teva Halts Phase 2 TOPAS-MSA Trial for Futility
01:37 Karyopharm Files Chapter 11 and Plans Ayrmid Merger
02:00 Alligator Out-Licenses Mitazalimab to Biossil
02:28 SEC Declares Chemomab-Scipher Merger S-4 Effective
02:49 Samsung Biologics Advances PolyPeptide Group Buyout
03:06 Enlivex Reports 12-Month Allocetra Topline Data
03:28 Looking ahead
04:01 SOZO Intuition
Summary
Today on the SOZO biotech daily, we track three major developments across the sector: INOVIO secures accelerated FDA approval for VOCERYQ in recurrent respiratory papillomatosis, Teva discontinues its Phase 2 study of emrusolmin in multiple system atrophy following an interim futility review, and Karyopharm Therapeutics enters Chapter 11 restructuring with plans to merge with Ayrmid. Sources are in the show notes.
Sources by chapter
Today's Lead Biotech Stories
FDA Grants Accelerated Approval to VOCERYQ
INOVIO receives FDA accelerated approval for VOCERYQ in recurrent respiratory papillomatosis 2026-11-02
INOVIO Confirmatory Trial and Launch Timeline
Teva Halts Phase 2 TOPAS-MSA Trial for Futility
Teva to discontinue Phase 2 TOPAS-MSA study of emrusolmin after interim futility analysis 2026-11-02
Karyopharm Files Chapter 11 and Plans Ayrmid Merger
Karyopharm announces planned merger with Ayrmid under Chapter 11 restructuring 2026-11-02
Alligator Out-Licenses Mitazalimab to Biossil
Alligator Bioscience to sell mitazalimab rights to Biossil for $0.75 million upfront 2026-10-31
Fresenius Kabi and WuXi Biologics sign exclusive biosimilars development agreement 2026-11-02
SEC Declares Chemomab-Scipher Merger S-4 Effective
Chemomab and Scipher Medicine S-4 registration statement declared effective 2026-11-02
Samsung Biologics Advances PolyPeptide Group Buyout
Samsung Biologics reports 97.66% provisional participation in PolyPeptide tender offer 2026-11-02
Enlivex Reports 12-Month Allocetra Topline Data
Enlivex reports 12-month Phase I/IIa Allocetra results in knee osteoarthritis 2026-11-02
Looking ahead
Mirum Pharmaceuticals presents Phase 3 brelovitug and Phase 2b volixibat data at AASLD 2026 2026-11-02
SOZO Intuition
Daily - Oct 30, 2026 — Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
Chapters
00:00 Today's Highlights
00:55 Pelthos and Castle Creek to Merge Operations
01:40 Merger Structure and D-Fi Development Plans
02:15 China Grants Priority Review for Hengrui's ADC
03:02 SHR-A1811 Met Primary Endpoint in Phase 3 Trial
03:47 Moleculin Completes Dosing in Part A of MIRACLE
04:24 MIRACLE Data Readout Slated for 2027
04:48 CLINUVEL Files NEURACTHEL Instant in Europe
05:15 Celularity Partners with Vesalius on Peptides
06:04 Repligen Announces $1B Convertible Notes Offering
06:40 Looking Ahead
Summary
Welcome to the SOZO biotech daily. Today we lead with a definitive merger agreement between Pelthos Therapeutics and Castle Creek Biosciences to establish a serious-skin-disease company centered on late-stage cell therapy, China’s priority review designation for Jiangsu Hengrui Medicine’s antibody-drug conjugate SHR-A1811 in advanced breast cancer, and Moleculin Biotech completing patient dosing in the initial stage of its registrational acute myeloid leukemia trial. Looking ahead, key developments to track include the initiation of the continued late-stage study for Castle Creek's lead gene-modified cell therapy, China's forthcoming regulatory decision on Hengrui's priority breast cancer submission, and Moleculin's upcoming data readout in 2027 to establish dose selection for the next phase of clinical evaluation. Sources are in the show notes.
Sources by chapter
Today's Highlights
Pelthos and Castle Creek to Merge Operations
Pelthos Therapeutics and Castle Creek Biosciences Agree to Merge Around a Phase 3 Dystrophic Epidermolysis Bullosa Program 2026-10-30
Merger Structure and D-Fi Development Plans
China Grants Priority Review for Hengrui's ADC
China's NMPA Grants Priority Review to Hengrui's SHR-A1811 for HER2-Positive Breast Cancer 2026-10-29
SHR-A1811 Met Primary Endpoint in Phase 3 Trial
Moleculin Completes Dosing in Part A of MIRACLE
Moleculin Completes Part A Dosing in Pivotal MIRACLE Trial of Annamycin in Relapsed or Refractory AML 2026-10-29
MIRACLE Data Readout Slated for 2027
CLINUVEL Files NEURACTHEL Instant in Europe
CLINUVEL Files NEURACTHEL Instant Dossier with European Regulators 2026-10-29
Celularity Partners with Vesalius on Peptides
Celularity and Vesalius Longevity Labs Sign Exclusive U.S. Manufacturing Collaboration for Peptual Peptide APIs 2026-10-29
Repligen Announces $1B Convertible Notes Offering
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction 2026-10-29
Looking Ahead
Daily - Oct 22, 2026 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
SUMMARY
Welcome to the SOZO biotech daily brief. Today, our lead stories cover an FDA accelerated approval for AstraZeneca in primary immunoglobulin A nephropathy, mid-stage clinical trial results from Lumen Bioscience in Clostridioides difficile, and a multi-target miniprotein discovery alliance between Astellas Pharma and AI Proteins. We also follow pipeline progress from Newron Pharmaceuticals and Thiogenesis Therapeutics, alongside new venture backing for Reju Therapeutics. Sources are in the show notes.
CHAPTERS AND SOURCES
00:00 - SOZO Biotech Daily Brief
00:34 - AstraZeneca's Ultomiris Wins FDA Accelerated Approval
Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A…:
https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html
01:38 - Lumen Reports Phase 2 RePreve Results for LMN-201
Lumen's LMN-201 shows positive RePreve Phase 2 results in C. difficile 2026-10-22:
https://www.lumen.bio/2026/10/22/lumen-s-lmn-201-shows-positive-re-preve-results-in-c-difficile
02:32 - Astellas and AI Proteins Form Miniprotein Discovery Pact
Astellas Pharma and AI Proteins enter miniprotein discovery collaboration valued at over $400 million 2026-10-21:
https://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million
03:18 - Newron Completes Phase 3 ENIGMA-TRS 1 Enrollment
Newron completes enrollment of pivotal Phase 3 ENIGMA-TRS 1 study of evenamide 2026-10-22:
https://www.newron.com/news-and-media/regulatory-news/newron-completes-enrollment-pivotal-phase-3-enigma-trs-1-study
03:54 - FDA Clears TTI-0102 IND in Nephropathic Cystinosis
Thiogenesis announces FDA clearance of IND for TTI-0102 in nephropathic cystinosis 2026-10-22:
https://finance.yahoo.com/healthcare/articles/thiogenesis-announces-fda-clearance-ind-090000510.html
04:29 - Nanjing Reju Therapeutics Closes Oversubscribed Series A
Reju Therapeutics completes oversubscribed Series A financing 2026-10-21:
https://www.vcbeathealth.com/article/63807
04:57 - Looking ahead
05:32 - SOZO Intuition
Daily - Oct 21, 2026 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
CHAPTERS
00:00 SOZO Biotech Daily Brief
00:35 Fenebrutinib Cuts Relapse Rate in Multiple Sclerosis
01:11 Fenebrutinib Slows Chronic Brain Lesion Progression
01:46 Genentech Highlights Pediatric Ocrevus and Enspryng
02:23 Miv-cel Shows 1-Year Mobility Gains in Stiff Person
03:00 Miv-cel Enables Immunotherapy Freedom at One Year
03:38 Oral Olorofim Meets Non-Inferiority in Aspergillosis
04:12 Olorofim Reduces Renal Injury; Resubmission Planned
04:48 FDA Approves ORLADEYO Oral Pellets for HAE
05:30 LMN-201 Biologic Cocktail Succeeds in Phase 2 C. diff
06:13 BIOX-101 Reduces Edema Growth in Brain Hemorrhage
06:56 Servier Partners with Okomera on Tumor Miniaturization
07:37 Looking ahead
08:24 SOZO Intuition
SUMMARY
SOURCES BY CHAPTER
SOZO BIOTECH DAILY BRIEF
FENEBRUTINIB CUTS RELAPSE RATE IN MULTIPLE SCLEROSIS
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21:
https://www.gene.com/media/press-releases/15139/2026-10-21/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026
FENEBRUTINIB SLOWS CHRONIC BRAIN LESION PROGRESSION
GENENTECH HIGHLIGHTS PEDIATRIC OCREVUS AND ENSPRYNG
MIV-CEL SHOWS 1-YEAR MOBILITY GAINS IN STIFF PERSON
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto…:
https://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.html
Quell Therapeutics Advances QEL-005 to Second Dose Cohort in CHILL Phase 1/2 Trial in Rheumatoid Arthritis and Systemic Sclerosis 2026-10-21:
https://www.biospace.com/press-releases/promising-early-safety-data-as-quell-therapeutics-advances-qel-005-a-novel-engineered-ntreg-therapy-to-second-dose-cohort-in-chill-phase-1-2-trial-in-difficult-to-treat-rheumatoid-arthritis-and-systemic-sclerosis
Arctic Therapeutics Closes Oversubscribed US$21.5 Million Financing 2026-10-21:
https://www.prnewswire.com/news-releases/arctic-therapeutics-closes-oversubscribed-us21-5-million-financing-302915211.html
MIV-CEL ENABLES IMMUNOTHERAPY FREEDOM AT ONE YEAR
ORAL OLOROFIM MEETS NON-INFERIORITY IN ASPERGILLOSIS
Shionogi and F2G Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome Followed by Standard of Care in Invasive…:
https://www.shionogi.com/global/en/news/2026/10/e20261021_3.html
OLOROFIM REDUCES RENAL INJURY; RESUBMISSION PLANNED
FDA APPROVES ORLADEYO ORAL PELLETS FOR HAE
BioCryst Announces U.S. FDA Approval of ORLADEYO 150 mg Oral Pellets for Adults and Adolescents with Hereditary Angioedema 2026-10-21:
https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html
LMN-201 BIOLOGIC COCKTAIL SUCCEEDS IN PHASE 2 C. DIFF
Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial of LMN-201 for C. difficile Infection 2026-10-21:
https://www.prnewswire.com/news-releases/lumen-bio-reports-positive-phase-2-results-from-the-repreve-clinical-trial-lmn-201-for-c-difficile-infection-302915046.html
BIOX-101 REDUCES EDEMA GROWTH IN BRAIN HEMORRHAGE
Bioxodes BIOX-101 Phase 2a Data Show Statistically Significant Reduction in Perihematomal Edema Growth in Intracerebral Hemorrhage 2026-10-21:
https://www.bioxodes.com/newsroom/press-releases/bioxodes-biox-101-phase-2a-data-show-statistically-significant-reduction-in-perihematomal-edema-growth-in-intracerebral-hemorrhage
SERVIER PARTNERS WITH OKOMERA ON TUMOR MINIATURIZATION
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research 2026-10-21:
https://www.okomera.com/_files/ugd/631ec0_f041bdf1df614649962c581bf1a5e735.pdf
LOOKING AHEAD
Akeso Announces Summit Therapeutics and ECOG-ACRIN Enter a Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer…:
https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.html
Muna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator MNA-001 in Alzheimer Disease 2026-10-21:
https://www.prnewswire.com/news-releases/muna-therapeutics-announces-positive-phase-1-results-supporting-potential-of-oral-small-molecule-trem2-modulator-mna-001-in-alzheimers-disease-302914619.html
Additional references omitted to fit YouTube's 5,000-character limit.
Daily - Oct 20, 2026 v2 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
CHAPTERS
00:00 Biotech Daily Briefing
00:43 RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
01:32 RAP-219 Validates Selective Mechanism in Acute Mania
02:12 Casdatifan Shows Efficacy in Renal Cell Carcinoma
03:02 Casdatifan Delivers 35-Month Median Overall Survival
03:46 Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
04:43 FDA Approves Process 2.0 for Alvotech's SIMLANDI
05:27 Ambrose Acquires AM-Pharma for up to 161 Million Euros
06:16 Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
07:06 Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
07:50 Looking ahead
08:31 SOZO Intuition
SUMMARY
Welcome to today's biotech daily briefing. Today, we lead with positive mid-stage clinical proof-of-concept data from Rapport Therapeutics in acute bipolar mania, expansive platform trial results from Arcus Biosciences evaluating casdatifan across multiple lines of clear cell renal cell carcinoma, and long-term extension data from Teva and Sanofi demonstrating sustained efficacy for duvakitug in inflammatory bowel disease. We also follow regulatory and clinical advancements spanning biomanufacturing, rare disease acquisitions, critical care respiratory medicine, and gastrointestinal oncology. Sources are in the show notes.
CHAPTERS AND SOURCES
00:00 - Biotech Daily Briefing
00:43 - RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
Rapport Therapeutics Reports Positive Phase 2 Results for RAP-219 in Bipolar Mania 2026-10-20:
https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htm
PolarityBio Phase 3 COVER DFUS II Meets Primary Endpoint in Diabetic Foot Ulcers 2026-10-20:
https://www.biospace.com/press-releases/polaritybio-highlights-highest-scoring-abstract-award-and-presentation-of-phase-3-cover-dfus-ii-trial-results-at-sawc-fall-2026
01:32 - RAP-219 Validates Selective Mechanism in Acute Mania
02:12 - Casdatifan Shows Efficacy in Renal Cell Carcinoma
Arcus Biosciences Presents ARC-20 Data for Casdatifan Across ccRCC Lines 2026-10-20:
https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm
03:02 - Casdatifan Delivers 35-Month Median Overall Survival
03:46 - Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
Teva and Sanofi Report 44-Week Phase 2b Data for Duvakitug in IBD 2026-10-20:
https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspx
Odyssey Therapeutics Reports Phase 2a OD-001 Data in Ulcerative Colitis 2026-10-20:
https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-ex99_1.htm
04:43 - FDA Approves Process 2.0 for Alvotech's SIMLANDI
Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process 2026-10-20:
https://www.biospace.com/press-releases/alvotech-receives-fda-approval-for-new-simlandi-manufacturing-process-that-more-than-doubles-output-per-batch
05:27 - Ambrose Acquires AM-Pharma for up to 161 Million Euros
Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million 2026-10-20:
https://www.biospace.com/press-releases/ambrose-healthcare-acquires-am-pharma-for-up-to-161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base
06:16 - Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
Nano24 Reports Positive Phase 2b Results for Inhaled EXO-CD24 in ARDS 2026-10-20:
https://www.businesswire.com/news/home/20261020667516/en/Nano24-Reports-Positive-Phase-2b-Results-for-Inhaled-EXO-CD24-in-Acute-Respiratory-Distress-Syndrome-ARDS-at-the-CHEST-Annual-Meeting-2026
07:06 - Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
Hengrui's Retlirafusp Alfa RELIGHT Phase 3 Results Published in JCO 2026-10-20:
https://www.hengrui.com/media/detail-1054.html
07:50 - Looking ahead
AstraZeneca and Oracle Launch Global AI Collaboration for Clinical Trial Optimisation 2026-10-20:
https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-oracle-launch-global-ai-collaboration-advance-clinical-trial-optimisation-support-better-patient-outcomes.html
Adocia Raises €7 Million and Extends Cash Runway to 2028 2026-10-20:
https://www.adocia.com/composants/uploads/2026/10/ADOCIA-PR-FINANCING-OPERATION-OCTOBER-2026.pdf
08:31 - SOZO Intuition
Daily - Oct 16, 2026 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
CHAPTERS
00:00 Today's Biotech Brief Lead Stories
00:42 FDA Approves Roche's Enspryng for Thyroid Eye Disease
01:17 Enspryng Clinical Profile and SatraGO-2 Efficacy
02:03 Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
02:39 Revita Significantly Reduces Post-GLP-1 Weight Regain
03:26 Mankind Pharma Acquires Majority in Armed Cell
03:56 Armed Cell Platform and Strategic Leadership
04:39 Regulatory Moves: Zilbrysq Autoinjector and Talvey
05:49 Financings and M&A: City Therapeutics and Samsung
06:48 Looking ahead
07:36 SOZO Intuition Platform
SUMMARY
CHAPTERS AND SOURCES
00:00 - Today's Biotech Brief Lead Stories
00:42 - FDA Approves Roche's Enspryng for Thyroid Eye Disease
FDA approves Roche's Enspryng satralizumab, a first-in-class IL-6R inhibitor, as the first at-home subcutaneous treatment for thyroid eye disease 2026-10-16:
https://www.roche.com/media/releases/med-cor-2026-10-16
01:17 - Enspryng Clinical Profile and SatraGO-2 Efficacy
02:03 - Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
Fractyl Health reports that Revita met the six-month co-primary endpoint in the pivotal REMAIN-1 study, cutting weight regain after GLP-1 discontinuation…:
https://www.globenewswire.com/news-release/2026/10/16/3382499/0/en/fractyl-health-s-revita-meets-six-month-co-primary-endpoint-in-ongoing-remain-1-pivotal-study-with-highly-statistically-significant-reduction-in-weight-regain-after-glp-1-discontin.html
Opus Genetics presents positive clinical data from the OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 2026-10-16:
https://ir.opusgtx.com/press-releases/detail/545/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-
02:39 - Revita Significantly Reduces Post-GLP-1 Weight Regain
03:26 - Mankind Pharma Acquires Majority in Armed Cell
Mankind Pharma enters CAR-T with a EUR 48 million deal for a 70% stake in Belgium's Armed Cell Therapeutics 2026-10-16:
https://www.mankindpharma.com/media/press-release/mankind-pharma-to-acquire-majority-stake-in-armed-cell-therapeutics-marking-strategic-entry-into-next-generation-car-t-therapies/
03:56 - Armed Cell Platform and Strategic Leadership
Acepodia receives TFDA IND approval for ACE723, expanding clinical development to the United States, China and Taiwan 2026-10-16:
https://www.acepodia.com/newsroom-detail/ACE723_IND_TW/
04:39 - Regulatory Moves: Zilbrysq Autoinjector and Talvey
UCB receives U.S. FDA approval for ZILBRYSQ zilucoplan autoinjector self-administration in generalised myasthenia gravis 2026-10-16:
https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-for-zilbrysqr-zilucoplan-autoinjector-self-administration-for-adults-living-with-generalized-myasthenia-gravis
CHMP recommends approval of Johnson & Johnson's TALVEY talquetamab plus daratumumab in earlier-line relapsed or refractory multiple myeloma 2026-10-16:
https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma
05:49 - Financings and M&A: City Therapeutics and Samsung
Samsung Biologics publishes the definitive interim result of its tender offer for PolyPeptide with an 87.92% participation rate 2026-10-16:
https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-definitive-interim-result-for-polypeptide-tender-offer
City Therapeutics raises $200 million in an upsized initial public offering, the largest biotech IPO pricing of the week 2026-10-16:
https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html
Soufflé Therapeutics raises an oversubscribed $135 million Series B to advance its RNA delivery platform 2026-10-16:
https://www.citybiz.co/article/919851/souffle-therapeutics-raises-135m-to-advance-rna-delivery-platform/
06:48 - Looking ahead
Shareholders of Indivior and Supernus Pharmaceuticals approve their all-stock merger of equals 2026-10-16:
https://www.indivior.com/latest/category/company-statements/2026/indivior-shareholders-approve-proposed-merger-with-supernus
Edesa Biotech receives FDA IND clearance for a Phase 2 study of EB06 in vitiligo 2026-10-16:
https://www.biospace.com/press-releases/edesa-biotech-announces-fda-ind-clearance-for-phase-2-vitiligo-study
Eclipse Life Sciences reports positive Phase 2 BETTIS-1 topline results for EC-104 in diabetic macular edema 2026-10-16:
https://www.globenewswire.com/news-release/2026/10/15/3381495/0/en/eclipse-life-sciences-announces-positive-topline-results-from-phase-2-bettis-1-study-evaluating-ec-104-for-diabetic-macular-edema-dme.html
Additional references omitted to fit YouTube's 5,000-character limit.
This digest covers key developments from AstraZeneca, insitro, Takeda, Krystal Biotech, Labcorp Holdings and OMass Therapeutics, including a billion-dollar AI target-discovery collaboration, the first orexin agonist launch for narcolepsy type 1, positive early dermatology clinical data in Gorlin syndrome, a $722 million diagnostics asset acquisition, an FDA-accepted NDA resubmission and a $310 million Series C, alongside broader coverage across the sector.
This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.
This digest covers key developments from Zealand Pharma, Arrowhead Pharmaceuticals, Pharming, Galderma, and Alentis Therapeutics, including a billion-dollar AI-designed protein collaboration, first-in-human tau knockdown data, a positive Phase II immunology readout, and a $1.5 billion dermatology acquisition, alongside broader coverage across the sector.
This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.
This digest covers key developments from BioNTech, Samsung Biologics, Johnson & Johnson, and Formycon, including Phase III readouts, a cross-border tender offer, and regulatory acceptances, alongside broader coverage across the sector.
This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.
From the publisher's feed